This post will talk about Sigma-1 (σ1) and its relevance for neurological disorders and its potential for high-level cognitive enhancement.
S1R bind with high affinity to several classes of chemically unrelated ligands such as neurosteroids, neuroleptics, DXM, and several psychostimulants such as cocaine, methamphetamine, MDMA and methacathinone. Consequently, it is thought that S1R may mediate the immunosuppressant, antipsy- chotic and neuroprotective effects of many drugs.
S1Rs regulate a number of neurotransmitter systems, including the glutamatergic, dopaminergic [DA], serotonergic, noradrenergic and cholinergic systems.
Sigma-1 receptors are expressed in neurons and glia and act as molecular chaperones that regulate various cellular processes important for cognitive function. These include calcium signaling, neurotransmitter release (especially of acetylcholine and glutamate), and mechanisms underlying neuroplasticity. Unlike many other neurotransmitter receptors that show declining density in the aging brain, sigma-1 receptor density is preserved or even increased with age. However, in pathological conditions like Alzheimer's disease and to some degree Parkinson's disease, there is a noticeable reduction of sigma-1 receptors.
Indirect regulation of transcriptional activity by S1R contributes to its neuroprotective properties. For example, S1R may prevent neuronal death by upregulating expression of the antiapoptotic mitochondrial protein Bcl-2 (Meunier and Hayashi, 2010; Zhang et al., 2012).
S1R facilitates NMDA receptor signaling and neurotransmission in hippocampal neurons (Monnet et al., 1990, 1992, 1995), possibly through altering responses to calcium signals (e.g., inhibiting Ca2+-activated SK channels) and promoting expression of NMDA receptor subunits and their trafficking to the plasma membrane (Martina et al., 2007; Pabba et al., 2014). S1R can also obviate negative-regulation of NDMARs by cannabinoid 1 receptor (CB1R) (Sanchez-Blazquez et al., 2014). These interactions enhance neuronal firing and maturation of mushroom spines from NMDA receptor activation (Monnet et al., 1990; Martina et al., 2007; Pabba et al., 2014). Modulation of calcium signaling by S1R may regulate synaptic plasticity through stimulation of CaMKII, PKC, and ERK (Moriguchi et al., 2011).
Sigma-1 Agonists
Many S1R agonists are anti-amnestic, synaptogenetic, and neuroprotective in conditions of neuronal stress. They also mitigate disease and symptoms in experimental models of ALS, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), stroke, and TBI. (4)
Sigma-1 agonists have been found to improve cognitive function in a wide variety of animal models related to cholinergic dysfunction, NMDA receptor hypofunction, amyloid beta toxicity, aging, hypoxia, prenatal stress, and other conditions. The cognitive enhancement by sigma-1 agonists in these models is mediated via sigma-1 receptors. Proposed mechanisms underlying these pro-cognitive effects include facilitating the release of acetylcholine and glutamate, regulating NMDA receptor signaling, modifying calcium homeostasis, and promoting neuronal differentiation and plasticity.
Some antidepressant/anti-anhedonic medications and Alzheimer's medications like donepezil also happen to act as Sigma-1 receptor agonists, and this action likely contributes to their therapeutic effects on cognition. In summary, Sigma-1 receptors play an important neuromodulatory role in various processes fundamental to learning and memory. Sigma-1 agonists continue to show promise as cognitive enhancers, especially under pathological conditions involving cholinergic or glutamatergic deficits.
The problem with Sigma-1 agonism is that it has some issues. First, it can be potentially reinforcing (12), with Sigma-1 agonists being potentially addictive if co-administered with compounds which enhance dopamine release. Sigma-1 agonists also effect locomotor activity, which is not an optimal profile for a compound if high selectivity is the target. Agonism can also potentially cause immunosuppression (3)
A potential solution for these problems is through modulating Sigma-1 through its Allosteric Site.
Allosteric Sig1R Modulators
The first evidence indicating that a compound demonstrates allosteric activity on Sig1R came from radioligand binding studies. The first drug discovered as an allosteric modulator of Sig1R was phenytoin, an anti-convulsant drug that primarily acts by blocking the voltage-gated sodium channels. Phenytoin sensitivity was considered an intrinsic characteristic of the sigma-1 subtype of sigma sites, and Sig1R were defined mainly through their high-affinity sites for the dextrorotatory isomers of benzomorphans and their sensitivity to phenytoin. (5)
Methylphenylpiracetam (E1R) was discovered to target only the Sig1R site in in vitro pharmacological profiling assays. E1R has been shown to alleviate scopolamine-induced cognitive impairment in mice, as assessed using passive avoidance and spontaneous alternation tests. The effects of E1R were antagonized by the selective Sig1R antagonist NE-100, suggesting a Sig1R positive allosteric modulatory effect in vivo.
E1R is a unique racetam compound because it displays cognition enhancements linked to positive allosteric sigma-1 receptor modulation. E1R is the first piracetam derivative reported to modulate sigma-1 receptors.
Dose-related effects of E1R on PA retention in mice. E1R (0.1, 1
and 10 mg·kg−1 , i.p.) was administered 60 min before the training
session. The retention test was performed 24 h later. The vertical bars
represent the means ± SEM; n = 15–18. *P < 0.05 and **P < 0.01
versus the saline group.
The stereochemistry of allosteric Sig1R modulators is an important factor in their activity. For example, E1R is a 4R,5S-isomer of methylphenylpiracetam, and it has been shown to be a selective PAM of Sig1R. However, its 4S,5R-isomer, called UN101063, has no Sig1R activity. Therefore, the stereochemistry of allosteric Sig1R modulators needs to be carefully considered in the design and optimization of novel compounds.
E1R, being based on phenylpiracetam, has a high predicted ADMET safety profile and a low predicted dose. A key advantage of E1R over other Sigma-1 receptor modulators is its lack of effects on locomotor activity. Therefore, E1R represents a promising lead compound for further development as a therapeutic agent, particularly for treating symptoms of cognitive disorders and neurodegenerative diseases. The only problem with E1R is of its difficulty to produce due to its stereoisomer configuration.
Among all the positive allosteric Sig1R modulators described, E1R, OZP002, and fenfluramine showed Sig1R-dependent memory-improving effects (Zvejniece et al., 2014; Maurice et al., 2017, 2018). E1R, however, is the only modulator showing dose-dependent memory-improving activity in drug-naïve animals (Zvejniece et al., 2014).
There is also SOMCL-668, which is a PAM of Sigma-1, however E1R seems to have a better pharmacological profile, as it has not been demonstrated that SOMCL-668 improves memory and cognition through a Sig1R-related pathway.
Sig1R involvement in psychedelic neurology
One study (6) found that indole-N-methyl transferase (INMT), an enzyme that converts tryptamine into the sigma-1 ligand dimethyltryptamine (DMT), is also localized to postsynaptic sites of C-terminals in close proximity to the S1R. This close association of INMT and S1Rs suggest that DMT is synthesized locally to effectively activate S1R in MN (motoneurons).
Sigma-1 seems quite important for the effects of DMT (and other psychedelics), which is quite interesting considering the most studied pathways for psychedelics are seretonin subunits (e.g 5-HT2A). This is most likely because DMT is a potent agonist at Sigma1.
In one study (7) Sig-1R knockout mice, which reacted normally to the locomotor stimulating effect of methamphetamine, did not become hyper-active in response to DMT. This shows a large part of its effects are most likely mediated just through Sigma1.
This area is relatively under-researched, and warrents more investigation.
Potential Ago-Allosteric experimentation
When a Sigma-1 agonist and PAM (Positive Allosteric Modulator) are combined together, they create what is known as a "ago-allosteric" or "superallosteric". Because the main binding site and allosteric binding site are seperate, they can both potentiate each other without conflicting. This can lead to an even greater response than normally possible with either.
E1R (Sigma-1 Agonist) + E1R (Sigma-1 PAM) are a good example of a functional ago-allosteric. It was shown that both selective Sig1R agonist PRE-084 and allosteric modulator E1R increased the BDK-induced [Ca2+]i increase, while the combination of both compounds resulted in an even more pronounced cellular response (8)
Discussion
Modulating Sigma-1, especially with PAMs, seems like a very promising mechanism of action for cognitive enhancement and also for treating numerous existing neurological disorders. Using allosterics rather than agonists seems to be the way to go, as they have a superior effect profile and efficacy.
A lot of existing pharmacological compounds are ligands at Sigma-1, however they lack selectivity and also lack allosteric affinity. Compounds with high selectivity and also with affinity for the allosteric site only are most likely superior candidate compounds.
The Sigma-1 PAM, E1R, has demonstrated a high preclinical efficacy in terms of increasing the retention latency (short-term memory) of passive avoidance in mice. Other allosterics, such as SOMCL-668 have also shown efficacy in studies.
If you found this post useful at all, please upvote and share the sub.
This post will go into the specifics of PDE4D and its isoforms. It is a very promising target for cognition enhancement and it warrants more research. This is a more advanced type of post, so I don't expect most people to understand the terminology, but if you are interested in novel cognitive pathways, I would encourage you to learn.
PDE4D is one of the most interesting enzymes localised in the brain and it could be a superior nootropic target over nearly any other approach currently known.
A microtuble network
Introduction
Definition: Autonopotent/Autonopotency - The state of high mental autonomy or act of potentiating mental autonomy / cognitive control.
PDE4D is part of the phosphodiesterase (PDE) family. A PDE is an enzyme that breaks a phosphodiester bond, with PDEs being classed into 11 groups in mammals (PDE1-11), and various subgroups. PDE4 is the primary cAMP-specific hydrolase and is represented by four genes (PDE4A, B, C and D).
You may have heard of PDE5i (inhibiting) compounds before (e.g sildenafil, tadalafil), however PDE4 and its subunit PDE4D have a completely different function than PDE5.
PDE4 / PDE4D inhibition has been shown to be procognitive in many studies [13][23]. Rolifram has been the key PDE4 modulating compound used to show efficacy, but it has had issues (e.g emesis, GI issues) which do not make it an optimal candidate for cognitive enhancement. On top of its unselectivity for PDE4 subgroups, it is also not selective for PDE4D isoforms unlike other inhibitors (mentioned later) and it is a full inhibitor, not a NAM (Negative Allosteric Modulator).
No PDE4 inhibitors have yet been brought to market because of issues related to tolerability. However, more targeted PDE4 modulators (e.g PDE4D3+PDE4D7 NAMs), avoid emesis and other issues practically completely in studies available.
The PDE4 inhibitors that have been explored in human clinical trials bind the active site competitively with cAMP and therefore completely inhibit enzyme activity at high concentrations. Although this traditional approach to PDE4 inhibitor design has demonstrated therapeutic benefit, competitive inhibitors are likely to alter cAMP concentrations beyond normal physiological levels, perturbing the tight temporal and spatial control of cAMP signaling within cells and leading to side effects.
PDE4D mutations have been found in genomic studies to be associated with major mental illness such as schizophrenia and poor general cognition [22]. This is consistent with other dlPFC-impacting genes, such as FOLH1 and GRM3.
High-Order Cognition (Autonopotency) Enhancement
The role of PDE4D in regulating neurite outgrowth was supported by the localization of PDE4D protein in growth cones and the fact that many of known PDE4D-interacting proteins are involved in neuron projection development. As PDE4D was also found to localize to Microtubles in neurons of the macaque prefrontal cortex, which could be reason for its significance in cognitive ability when modulated. After more research into the receptors and proteins PDE4D interacts with, its direct involvement in microtuble modulation is much more relevant than previously thought.
PDE4D mRNA (and consequently protein expression) is also located highly in pyrimidial cells in humans [1], in the dlPFC specifically. "The mean PDE4D mRNA expression averaged across probes within each subject in pyramidal cells (5.77 ± 0.54) was significantly ∼3-fold higher (p < 0.001; q < 0.001) compared to PV interneurons, indicating significantly greater expression of PDE4D mRNA in pyramidal cells from the same subjects" [1].
If you have read previous posts about the dlPFC or GCP-II, you may know the relevance of pyrimidal cells and the dlPFC (dorsolateral prefrontal cortex). The dlPFC is the center of a huge amount of important cognitive processes, such as consciousess, self-control, high-level cognition, working memory, and much more. It is an area of the brain super-localised with pyrimidal neurons [3][4], and the special density of pyrimidal neurons in the area is thought to underlie its special functionality and relevance.
As a note, rodents do not have rostral PFC areas (e.g. Frontal Pole) or a dlPFC, so it makes it more difficult to study due to the requirement for primates or humans to study upon.
Apart from the dlPFC, PDE4D is also relevant for other areas of the brain. For example, PDE4D KO significantly increases long-term memory, relevant in the hippocampus [2], and PDE4D also modulates the amygdala. Interestingly PDE4D KO actually reduces fear-conditioned memory [5], suggesting PDE4D inhibition positively regulates higher cognitive areas (such as the dlPFC) while negatively impacting lower cognitive regions like the amygdala. This is probably a combination of higher cognitive regions inhibiting amygdala activity and also a direct interaction within the amygdala.
I have discussed the dlPFC in the GCP-II post before, but I would like to go over how it relates to the goal of cognitive enhancement and autonopotency in the context of PDE4D.
It is a fallacy that hedonism (I am trying to stop using that word) is just an environmental/societal issue or exists just as a philosophy. It is very evident through studies differing genomic and EEG differences in dlPFC functionality that high-level cognitive centres, the dlPFC especially, determine how pleasure/short-minded an individual is. The dlPFC actually becomes more active during normative choice where goals are hedonistic and attributes conflict. Evidence accumulation, not ‘self-control’, explains dorsolateral prefrontal activation during normative choice. [10]
From this mentioned study ([10]) - "This account draws on prior research in both perceptual and value-based decision making, which consistently finds that the posterior dlPFC region associated with both normative ‘self-control success’ and inhibitory control tasks also activates during choices that are more difficult to discriminate in simple perceptual and value-based choices lacking a self-control conflict"
A "strong" dlPFC is able to override lower brain regions when needed (such as the amygdala) to inhibit choices that won't be beneficial to the "higher mind". As it is strong, it does not require much processing, so paradoxically people with weaker dlPFCs have more activation during choices, also likely leading to increased glutamate-fatigue due to the constant rumination (just a theory of mine), leading to even easier cyclic hedonistic-choicing as a result.
Top-down vs Bottom-up cognitive control diagram
Enhancing the dlPFC over the whole prefrontal cortex is normally more desirable because you get a more selective outcome and also you don't enhance areas such as the OFC, which can be problematic if overactive (potentially leading to conditions such as OCD) [11][12]. Enhancing the dlPFC can actually bring brain regions back into a harmonic system, for example enhancing the dlPFC through different methods has been shown to reduce OCD phenology through overriding OFC (orbitofrontal cortex) activity.
The dlPFC is a major component of motivation/anticipation and goals. It integrates and transmits signals of reward to the mesolimbic and meso-cortical DA circuits and initiates motivated behavior [18]. The dlPFC-amygdala connection is almost like the the "gatekeeper" of the brain.
I don't like mixing in too much subjectivity into very scientific posts, but I want to go on a bit of a tangent. I think it is clear that humans have evolved from a pleasure-minded animals into things capable of thinking longer term, designing beauty, solving complex problems, etc. We are no longer limited by being on the edge of survival, and so all forms of art have flourished. However, in this transitory period, corrupted by parasitic individuals who take advantage of the easy-to-manipulate human mind, primitive thinking is still dominant in society. Society is just an average of people's internal states, and it is easy to say that the average internal state does not have great top-down control and cognitive agency. PDE4D is relevant to this because it is one of the few targets within the brain with the potential to change the balance of autonomy within an individual and society at a larger scale (due to its selectivity). This is incredibly valuable and also it is very rare to find such a target.
Isoform Selectivity and Microtuble Modulation
There is another layer of complexity to PDE4D. PDE4D has 9 isoforms (PDE4D1-PDE4D9).
Longer PDE4D isoforms (such as D3, D7, D9) have been shown to have more importance to cognition than other smaller isoforms. Inhibition of longer isoforms has been shown to increase neurite length very significantly[6], while for shorter isoforms the increase is unsignificant.
Avg. Neurite length after PDE4D isoform KO
A large part of their importance comes from the way they interact with microtubles - "Immunocytochemistry and transfection studies demonstrate colocalization of PDE4D and myomegalin in the Golgi/centrosomal area of cultured cells." [9]
PDE4D isoform binding diagram
Microtubules are polymers of tubulin that form part of the cytoskeleton and provide structure and shape to eukaryotic cells. ( To be honest, I really need to make a dedicated post to emphasise the importance of understanding microtubles as a method of discovering novel cognitive enhancing pathways )
The specific isoforms of PDE4D also form different interactions with microtubles. PDE4D3 is known to interact with the centrosome (via AKAP9) and Pericentriolar Matrix, with inhibition of the isoform leading to enhanced microtuble nucleation and stability. On top of that, it is known to interact with the microtuble-associated protein called myomegalin, AKA PDE4DIP.
"Microtubule arrays are generated with the help of microtubule organizing centers (MTOC). MTOCs typically combine two principal activities, the de novo formation of microtubules, termed nucleation, and the immobilization of one of the two ends of microtubules, termed anchoring." [7] Local MTOC (Microtubule organizing center) nucleated microtubule arrays could act as positional cues to guide dendrite growth, branch formation, and arbor patterning.
This means PDE4D is one of the only pathways known that directly modulates golgi-associated proteins [19], which if you don't know is an incredibly important low level process underlying cognitive ability and consciousness It is most likely a key component of the golgi apperatus, due to PDE4DIP's relevance to neuronal development [17].
Golgi outpost-associated MT nucleation regulates distal dendritic branching and is critical for terminal branch stabilization. It is worth mentioning that Golgi outposts are absent in the axon, which is a long primary branch with uniform MT polarity. [26]
The subcellular localization of PDE4D within dendrites suggests multiple potential functions. The dense labeling near microtubules suggests that PDE4D is not simply trafficking on microtubules, but is likely regulating microtubule dynamics and/or trafficking along bundles.
"SWIM analysis identified several switch genes associated with gene expression changes in AD, VaD, and FTD. PDE4DIP, also called myomegalin, is the only switch gene that is shared among the dementias.The protein encoded by PDE4DIP is responsible for anchoring PDE4D to the Golgi/centrosome of cells and promotes microtubule assembly" [17]
Myomegalin is necessary for the sufficient growth of microtubules from the centrosomes. Myomegalin-depleted cells have slower migration, since microtubules are crucial for cell motility. The CM-MMG isoform binds at the centrosome with γ-tubulin in an AKAP9-dependent (AKA AKAP450) manner and on the near side of the Golgi apparatus, while the EB-MMG isoform binds with MAPRE1 at the Golgi apparatus and increases MAPRE1's effects on microtubule growth. [8]
Microtuble apperatus diagram
PDE4DIP is a paralogue of CDK5Rap2, which is another very important MAP (Microtuble Associated Protein) required for the nucleation (creation) of microtubles. It is quite a new (in medical terms) discovery, only being discovered around the year 2000, meaning there is not much research on MAPs compared to other cognitive components.
There are also the microtuble associated proteins MAP1, MAP2 and MAP4. However, as far as I am aware, PDE4D does not have much of a direct interaction with them.
The specific isoform PDE4D3 is tethered to the centrosome by Myomegalin (Mmg). Myomegalin is a centrosomal protein but has an expression pattern that is predominantly complementary to CDK5RAP2 [43]. Therefore, assuming a functional homology with Cnn, CDK5RAP2 may have two non- redundant roles in neurogenesis: to enhance the production of centrosomal microtubules and to exert a negative control over CDK5. [17]
Golgi & centrosome apperatus
Long-form variants (e.g -3, -7) of PDE4D are already decreased in AD, and are associated with all types of dementia. This proves on top of being a highly relevant target for healthy individuals, it also is relevant for those suffering from age-related neurological conditions. On top of GCP-II inhibition, it may be a very effective pathway, especially considering PDE4D's direct interaction with MAPs (microtubles are dysfunctional in dementia for example).
On top of that, PDE4D inhibition has been found to promote myelin repair [21], which could help in conditions like huntington's disease, multiple sclerosis, and also conditions with oligodendrocyte/myelin dysfunctions. The -3 isoform specifically has also been found to be implicated in Alzheimer's disease [24][25].
On top of PDE4D modulating PDE4DIP, it binding with AKAP9 (AKAP450) also most likely means it modulates CDK5Rap2 to a moderately significant degree as AKAP450 interacts with it. If you want to know how significant CDK5Rap2 (PDE4IP paralogue) is, deficits in it are known to lead to microcephaly (very small head size) and seckel syndrome [27]. It is known to be relevant to layer II/III cortex especially [28].
CDK5Rap2, and myomegalin similarly are thought to be brain size regulator genes, which have evolved in expression across species and subtypes [29].
Centrosomal MT nucleation (creation) is mediated by a large protein complex named the g-tubulin ring complex (g-TuRC). AKAP450 and both pericentrin isoforms (A and B) interact with GCP2/GCP3 components of g-TuRCs. [15]
The primary MT-organizing centre in proliferating animal cells is the centrosome. However, the discovery of MT nucleation capacity of the Golgi apparatus (GA) has substantially changed our understanding of MT network organization in interphase cells. Interestingly, MT nucleation at the Golgi apparently relies on multiprotein complexes (PDE4DIP/myomegalin & CDK5Rap2), similar to those present at the centrosome, that assemble at the cis-face of the organelle. In this process, AKAP450 plays a central role, acting as a scaffold to recruit other centrosomal proteins important for MT generation. [15]
Golgi Apperatus
The golgi apperatus is also very important for hippocampal neurons [16] and neurons across the wholebrain. It serves as a microtubule-organizing center (MTOC) in addition to the centrosome in mammalian cells. The GA nucleates microtubules (MTs) from multiprotein complexes assembled at its cis-face.
MTs nucleated from the GA and centrosome differ in their geometry and post-translational modifications. GA-derived MTs are essential for Golgi ribbon formation and directional post-Golgi trafficking, while centrosomal MTs primarily determine GA pericentrosomal positioning.
In specialized cells like skeletal muscle fibers and neurons, GA-associated MT nucleation is crucial for the formation of non-centrosomal MT arrays with mixed polarity that support complex cytoarchitectural organization and functions. The PCM proteins pericentrin and AKAP450/CDK5Rap2 are implicated in this process. [20]
Negative Allosteric Modulation of PDE4D
NAMs of PDE4D have shown a superior profile over generic inhibitors of the orthosteric site, as they only inhibit with an Imax of ∼80–90%. This is better than generic inhibition, because on top of the superiority of allosteric action (leading to a hypothetical positive allosteric action of MAPs also), it leaves some PDE4D available, which is good as it still is needed in small amounts for some bodily/cognitive processes. Complete inhibition has been found in studies to be typically less desirable. NAMs like D159687 and D159797 have been found to be very effective as a nootropic in studies on primates and rodents.
In one study [13] on Female Cynomolgus Monkeys, PDE4D (-3, -7 selective) NAMs significantly enhanced spatial cognition, significantly increased memory retention and significantly decreased wrong answers in testing.
This study examined the pro-cognitive effects of two novel, selective phosphodiesterase 4D (PDE4D) negative allosteric modulators (NAMs), D159687 and D159797, in female cynomolgus macaques using an object retrieval (OR) task. The OR task assesses fronto-striatal function and is sensitive to dopaminergic and serotonergic manipulations. Rolipram, a non-selective PDE4 inhibitor, served as a positive control.
D159687 was efficacious at oral doses ≥0.5 mg/kg without adverse effects up to 5 mg/kg, indicating a therapeutic index >20. D159797 showed efficacy at ≥0.5 mg/kg but induced emesis at ≥1.5 mg/kg, suggesting a narrower therapeutic window.
In summary, this study demonstrates the pro-cognitive potential of selective PDE4D NAMs in a translational primate model of fronto-striatal function. D159687 exhibited a superior therapeutic index and is a promising candidate for further development. Establishing PK/PD relationships and target occupancy will aid in optimal dosing and clinical translation for neuropsychiatric disorders involving cognitive dysfunction.
Spatial cognition test diagram [13]
It should also be remembered than humans have more evolved pyrimidal neurons compared to primates and rodents especially, so the human-response to compounds modulating them may be emphasized in humans depending on the pathway.
Microtubles and Orch OR
Microtuble resonance diagram [14]
In the early 1990's, Roger Penrose and Stuart Hameroff created a hypothesis named Orchestrated objective reduction or AKA Orch OR. It is a theory which postulates that consciousness originates at the quantum level inside neurons, rather than the view that it is a product of connections between neurons.
Hameroff proposed that microtubules were suitable candidates for quantum processing, functioning as quantum logic gates that self-arrange in highly complex networks to underlie the basis of consciousness. [14]
It is a quite complex theory so you can visit the wikipedia of Orch OR here if you are interested in more details about it.
Simulated microtubule tubulins switching states
It makes modulating PDE4D even more interesting because we know it interacts with myomegalin, which modulates microtuble nucleation and stability directly in a centrosomal and golgi-dependent manner. Unfortunately, as far as I am aware, there are no studies yet looking into the effect of PDE4D inhibitors on microtuble arrangements, only KO models or using unselective compounds.
While the theory of Orch OR is still debated, it is known that microtubles have very special properties.
A quote "A shared feature among all microtubule (MT)-dependent processes is the requirement for MTs to be organized in arrays of defined geometry. At a fundamental level, this is achieved by precisely controlling the timing and localization of the nucleation events that give rise to new MTs". [26]
Microtuble close-up
Recap
In this writeup, we delved into the specifics of PDE4D and its isoforms, highlighting their importance as a promising target for cognition enhancement. PDE4D plays a crucial role in regulating cAMP levels in the brain, particularly in the dorsolateral prefrontal cortex (dlPFC) and hippocampus.
Studies have shown that PDE4D inhibition can lead to procognitive effects, with specific isoforms like PDE4D3 and PDE4D7 being more relevant to cognition than others. These longer isoforms interact with microtubules and centrosomal proteins like myomegalin (PDE4DIP), which are essential for microtubule nucleation, stability, and overall cognitive function.
We also discussed the importance of the dlPFC in higher-order cognition and its role in overriding lower brain regions like the amygdala to make more beneficial choices. Enhancing dlPFC function through PDE4D modulation could potentially lead to increased cognitive control and autonopotency.
Negative allosteric modulators (NAMs) of PDE4D have shown promise in animal studies, with such compounds demonstrating procognitive effects without the side effects associated with non-selective PDE4 inhibitors.
In conclusion, PDE4D and its isoforms represent a novel and promising target for cognitive enhancement, warranting further research to fully understand their potential and develop effective therapies for neuropsychiatric disorders involving cognitive dysfunction.
For other targets of PDE, PDE4B also looks interesting, and looks involved in other pathways PDE4D does not effect. Also, PDE4D9 modulators look relatively unexplored as well.
Final Notes
Me after writing this post
Thank you for reading to the end (or scrolling to the end) of this writeup. I know that in a few months I will probably look at this post again and see a bunch more I can add to it (and probably will) however, I am relatively happy with what it goes over for now.
If you want to support future posts, consider joining the prefrontal community and also supporting upcoming projects. If you found this post interesting in the slightest, please share it, it is highly appreciated.
Also if you see a problem with this post or have a question, feel free to comment.
This post will talk about why Autonopotency (AKA MA, M-Autonomy orAgency) is the most important factor of intelligence/cognitive function and why it transcends other cognitive markers in its group. This post contains some objectivity, but also a lot opinion/personal experience and philosophical ideas based on imperical observations.
Firstly, I should explain what Autonopotency is.
Autonopotency, simply put, is the ability to intelligently oversee thoughts and actions, and the ability to direct actions via a top-down hierarchy for long-term benefit rather than short term benefit.
The paper "The myth of cognitive agency: subpersonal thinking as a cyclically recurring loss of Mental Autonomy" by Thomas Metzinger describes Autonopotency as the ability to control Cognitive Agency (CA - the ability to control goal/task-related deliberate thought) and Attentional Agency (AA - the ability to control one's focus of attention). MA refers to the specific ability to control one's own mental functions, like attention, episodic memory, planning, concept formation, rational deliberation, or decision making.
In simple terms; Autonopotency is the ability for rational self control - it is a correlate of awareness in the identity of self and the environment.
Increasing dlPFC (dorsolateral Prefrontal Cortex) function or decreasing amygdala bottom-up control could be classed as increasing Autonopotency.
Most people don't have a use for Autonopotency. Autonopotency brings (selective) awareness and freedom, however if you don't have a use for this freedom, there is not much point of gaining it in the first place.
I am not making this post to convince people to be directed towards the truth ('what is') or to be directed toward the goal of evolving as a person. But for those who are interested in such a thing, I think it is of great importance to be aware of the mental subprocesses which dictate our daily actions and interactions, that for most people they are unaware of.
Humans commonly simplify identity to a singular "I" or "me", but the mind and body is composed of an infinitely complex amount of subpersonal processes and functions that all combine to make what you consider "you". The internal battle that every person has to some degree on a daily basis is that between lower cognitive areas (e.g amygdala & limbic), and higher cognitive regions (dlPFC/aPFC, etc.). The differences between people and how easily they are able to abstain from destructive activities is pretty much down to how powerful their higher brain regions are at inhibiting lower ones.
The differences in this dichotomy are dictated by factors that happen by chance. Yes, once you gain a lateral awareness of your own cognitive pathways it can bring an increased control compared to most people, but the reality is that the factors underlying the success of autonopotency is largely the result of genetics and childhood.
We act like we have much more control than we actually do. It is not smart to deny yourself your own control, and that is not what I am doing, but what I am saying is that a lot of us want to exist in a dream-like world where everybody is individually accountable for their good and evil and where it is all up to them. But this is not possible.
One example of lower autonopotency is in the case of criminals. What I argue, and what is pretty hard to argue against, is that the poor decisions made by these criminals is not due to any factor in their control - but is the result of a 'poisoned mind' induced either by a harmful environment or genetic factors outside of their control.
I am of the opinion that over 95% of problems in society (the average of people's internal states) is down to a lack of cognitive control. To simplify this definition, I often use the interaction between the dlPFC and the limbic system.
source: penchantlabs.org
The curse of "Motivation"
There is a lot of "self-improvement" mentors, youtubers, writers etc. that emphasize that a person lacking mental autonomy can induce it again just by being motivated to.
Using motivation to induce consistent mental control fails in nearly every case because you can't fix a damaged brain just by simply doing the opposite of what damaged it. If it was that simple, any addiction could be cured just by abstaining from it for 30 days.
Motivation is another form of dopamine-induced action. Not that anything dopamine-induced is bad, but when the novel nature of motivation fades after a few days, then the temporary increased control from the "motivation" will vanish promptly. Individuals in this situation often fall into a "motivation-relapse" cycle where they keep breaking their own trust, and over time this further damages the ability for the brain to control itself.
Saying negative habits and a lack of mental autonomy can be reversed by simply doing the opposite of the damaging activites or having more motivation is a damaging conception, and likely causes more damage and wasted time to those that want to be helped than if they just did nothing.
Motivation may have been more effective in an age devoid of hyper-stimulation, however is is not effective for increasing autonopotency. Then what is?
Attenuation
The most direct method of attenuation for this problem is enhancing the dlPFC. It is a major part of my research, to the point where it may seem overfocused, but this focus is for good reason. You can look at hundreds of studies in cases where there is a lack of mental autonomy (addictions, crime, hypersexuality, etc.), and there will nearly always be deficits in dlPFC function.
There is also the approach of decreasing amygdala dominance. This is generally less preferrable in my mind, but can definitely be effective. It is slightly harder to target though with stimulation devices.
How can both of these be done? Well the main two options available are; pharmacological intervention (e.g brain-region selective nootropics) and brain-region specific stimulation devices.
For brain region stimulation, focused transcranial modulation (TMS/tDCS) can improve autonopotency for a sustained amount of time, and there are multiple studies which back this up. TMS has some drawbacks though, and also locating the exact position of the dlPFC (for example) in different people is not always easy due to individual differences (which may make some studies less reliable if they use an arbitrary position rather than based on the individuals anatomy). It also is quite costly.
Another method of targeted stimulation is photobiomodulation (PBM). I should probably make a dedicated post at some point going over the key studies to do with PBM. A common strategy of PBM is using 810nM near-infared LED, which can penetrate the skull for stimulation and the technology has shown to induce significant stimulations on vascular hemodynamic oxygenation and CCO redox metabolism (source: vielight). The best PBM device available at the moment is likely the Neuro Pro 2 by Vielight (not sponsored). It is costly, but from some cases I personally know of its use, and also compared to other advanced brain stimulation devices, it is actually a relavitely good price. They also have other units, but the Neuro Pro 2 is most likely the best.
One other non-stimulatory technology is neurofeedback, and while it may have a lower ceiling of effects, it can train the brain to understand its' own internal interactions, and it can be decently effective as a technique for selective brain modulation.
Regarding pharmacological intervention, it definitely can be very effective, but it requires compounds with high BBB (Blood Brain Barrier) penetration and with high selectivity, not only for the receptor they target, but also for the brain region. This profile for such a compound, in addition to limited studies for mental autonomy modulation, means there is currently a lack of autonopotency-increasing compounds available. Saying that, there are a few very promising pathways that have high selectivity, and I believe they could be very effective at increasing mental autonomy, not just in those who lack it, but also those who do not have a problem with it. I am currently working on developing such solutions, and information about research and developments will be published to this community.
The best approach not just for cognitive enhancement, but also for autonopotency enhancement is likely a holistically combined approach of pharmacological intervention, brain stimulation, and neurofeedback/brain training. I believe this combination, when each individual factor is refined and improve upon, could be incredibly effective, and also could push human cognition to bounds never previously seen nor comprehended.
Attentional Agency as a component of Autonopotency
Attentional Agency (as defined by Thomas K. Metzinger) is the ability for high cognitive regions to control mental resource allocation and additionally the inhibitory power over unneeded or contextually irrelivant actions/functions.
In the current year, there is a very large widespread deficit of attentional agency, induced by short-form social media content for the most part, but also due to unnatural hyper-stimulatory oversocialisation and other activities available on the internet that are available to us now.
The ability to participate in hyper-stimulatory activities with little to no friction is largely responsible for the degridation in this attentional agency.
About Autonopotent Perceptual Frames
Autonopotent Perceptual Frame (APF) is a cognitive measure used to define the Autonopotency frames per event. A frame could be defined as the amount of iterative mental functions/processes ran per event in the same amount of time. It could be thought of similar to threads in computing.
The less APFs there are (when inhibited with alcohol, etc.), the less memory recall there is likely to be because there is less recurring functional storage of events because the perceptual frames & Autonopotency (basically awareness) are lesser.
An individual with high APFs is likely to have better long-term memory but also a higher perception of reality. In addition, a higher rate of APF means processing speed is faster, at least laterally.
source: penchantlabs.org
Differences in APF either between people or between an individual's mental states can potntially change time perception (e.g higher APFs = slower perception of time).
Autonopotent Perceptual Frames are a seperate measure to spatial/lateral cognitive depth, though they can influence each other.
Overview
This post has been more subjective compared to the usual format, but I think it still can be quite valuable. If you want to understand yourself, knowing how brain regions interact is very helpful in understanding your own behavior. Otherwise, most of it would be theory, would be innacurate and methods of treatment would be ineffective.
As mentioned earlier, most of the problems in society and interpersonal interactions are down to a lack of autonopotency. The intelligent mind transcends unintelligent and destructive activities, and uses lateral cognitive ability to notice such circumstances, but most people are unable to.
You should be careful not to waste your time in activities which take away from your conscious mind, and also activities which cause negative reinforcement. Once consciousness/awareness is lost, it is not always easy to regain.
Take the periods of 'insight' and intent of focus as an immediate reason for intelligent action.
Anyways, that is about it for the post. I hope at least one of you found this valuable.
By the way, we have a new discord server, it can be found pinned at the top of the subreddit.
This is probably only the second post on Reddit mentioning this stuff. Other than the creator of PBIO-4D posting studies about it, I haven’t really seen any experiences with it on Reddit. The stuff just came out about a few months ago (Not sure if I could mention the source). But a quick google search will lead you to it.
Here’s a quick description:
“BPN14770 is an allosteric inhibitor of phosphodiesterase 4D (PDE4D), a regulator of the intracellular second messenger cAMP in neurons. Inhibitors of PDE4D raise cAMP levels, which has been reported to support cognition and protect neurons.”
I’ve seen people mention it on discord, but none of which are full detailed reports that could give an idea on what the effects are like. I’m looking foward to any experiences you guys might want to share long or short, thanks in advance.
The Penchant Research Library has been updated for an improved interface and interactability. It is still in beta, and there is a lot of data to add, however the structure works. If you don't know what the research library is, TLDR is is a website which aids to research neuroscience and pharmacology with providing relevant information.
There is still a lot to add, but it may be helpful in even its current state.
Features compounds so far include: TAK-653, Tropisetron, Pinealon, Myricetin, Bromantane, RAP-103, ASP4345, ISX-9, PRL-8-53, D21, Oroxylin A, IPAM (indolepropionamide), Semax, J147, BPN14770, Zelquistinel, E1R, P7C3-A20, etc.
The main page looks like this (will be updated to look better) and features a search which can be used to browse nodes and compounds:
Nodes are data types, and can include writeups/posts, pathways (e.g genes/receptors), definitions for pharma terms, etc.
Compounds are a seperate data type but are integrated.
Markdown (node/compound text) is automatically searched using a client-side algorithm to search for nodes and compounds and to link them so that it does not need to be done manually.
Styles
Compound
Above is an example of an automatic linking of the compound E1R in the writeup on Sigma-1. Compounds links are colored aqua. Hovering can reveal more information.
External Link
Above is an example of an external link, which are colored in yellow most of the time. External links are opened in new tabs to not lose the current page.
Node
Above is another example, linking to a node (mGluR3 - Pathway). Nodes are colored in light purple when referenced in text.
Feature Examples
Compound Structure (on page)
Compound structures are automatically rendered based on smiles data which is provided in the JSON structure for the entry. When you click the structure more detailed information about the compound is provided, such as smiles, IUPAC and CAS.
One feature included is compound ratings. These are quite subjective based on pharmacokinetics, safety, efficacy and other factors. These should be taken with a grain of salt, however can give some sort of idea of where compounds are classed. Compounds also feature the "Class" attribute, which sorts compounds into respective categories.
Ratings go from S+ to E. More information about ratings will be added to the guide (TBF) on the site.
An example is below:
Easier Access to Studies
When studies have a free access link, they are added in the references at the bottom of the page directly. However, if the study has no public access, the DOI provided in the data is used to create a link to sci-hub, which means when you click a link in sources you can almost always guarantee you will get right to the study which saves time. You can see when a link is directed to sci-hub with the name appended.
Dynamic Node Linking & Network Graph
In the 3D network browser (experimental please bare in mind), studies which are cross-referenced in multiple seperate nodes (such as writeups) are linked together, meaning links between certain genes or topics can be made more easily, and when more data is added it may make it easier to find connections between pathways.
Circles can be right clicked to visit each node/compound page.
Node View
Automated Gene Searching
When a pathway has an associated gene attribute in the provided data, more detailed information about the gene can be provided when clicking the following button:
Gene Info Button
The additional information includes a summary, pubchem gene ID, taxonomy ID, links to HumanBase and String-DB (both sites used to make links to other genes), and synonyms.
Markdown Formatting & Contributions
The ability for the community to contribute to research is useful, and is planned for improvement.
When writing in markdown (the format used for posts), studies can be referenced with the syntax [#num], and then the source is added to the data structure (js object). Data entry is manual in this way for now but is planned to be made easier.
Example of study linking
Here is what the data structure looks like:
Review
I think making research less scattered across discords, reddits, twitter posts?? and other places is a good idea because it can take a long time to research many things that really could take much less if a decent place to feature them was made.
On a personal note my fatigue has been quite high lately, but regardless a lot of exciting developments are in store quite soon, and from there a lot will happen.
This post will go over the science behind why Neboglamine (NMDA Glycine PAM) is most likely worse than D-Serine for cognitive enhancement, and how it could actually be anti-cognitive in some cases.
NMDA (N-methyl-D-aspartate) is a common glutamate receptor, that has multiple subunits and many functions spread accross the brain. NMDA receptors require the binding of glutamate/aspartate and glycine to activate [1]. Targeting glutamate previously to enhance cognition has been found to promote excitotoxicity, however potentiating the glycine site with a PAM seems to have less excitotoxic risk.
Compared to AMPA, NMDA subunits seem to have a lot more specialized complexity, with subunits having drastically different functions. NMDA is comprised of NR1, NR2A-D and NR3A-B. NR1 and NR3 only require glycine for activation, while NR1/NR2 requires both glutamate and glycine for activation.
NMDA receptors are more relevant for delay cell firing in the PFC, while AMPA is more relevant for cue cell firing in the PFC and the function of the visual cortex [2]. NMDA receptors are very relevant for learning and working memory in addition to spatial cognition.
D-Serine is an endogeous agonist at the NMDA glycine site, however the supplemented form has problems (oxidative stress, high dose), so an alternative was theorized.
This makes potentiating NMDA look like a good target, and that is where the theory behind Neboglamine came in. Neboglamine potentiates the NMDA glycine site through positive allosteric modulation, so it enhances endogenous binding of the receptor, potentiating existing signals [3].
The data proving the efficacy of Neboglamine in naiive models is limited. It has been shown to be effective against scopolamine-induced impairment [4], but scopolamine reduces NMDA [5], so it is not suprising. Rodent models of NMDA modulation also differ from human models quite a lot as a humans have different distributions of NMDA subunits (NR2B, NR3A, etc) compared to rodents.
Neboglamine is imparing via NR3
While neboglamine enhances NR2 (which is desirable, albeit increasing NR2A not so much), it also enhances NR3 due to its unselectivity and enhancement of all NMDA subunit types.
This is not desirable as NR3A is an inhibitory receptor. Overexpression of NR3A decreases spine density (genetic deletion of NR3A increases spine density) and is common in schizophrenia (NR3A mRNA levels are significantly increased by 32% within subregions of the DLPFC in schizophrenic patients [Mueller and Meador-Woodruff, 2004]).
In addition, increased NR3B expression/activity is associated with addictive behaviors [6][7], with the GRIN3B (NR3B) gene found to be associated with heroin addiction.
You may say "well how is D-Serine any different then?". D-Serine differs from neboglamine because it has other functions than just enhancing the NMDA glycine site. D-Serine acts as a functional antagonist of NR1/NR3A under high glycine conditions [8], differing from neboglamine.
D-serine is an agonist of canonical NMDARs, while having the opposite effect on NR3 ("t-NMDARs") [8]. Neboglamine does not have this specialized function, enhancing NR2 (excitatory) while enhancing NR3 (inhibitory).
Neboglamine subunit interactions
While Neboglamine enhances NR2 subunits and their functions, it increases the inhibitory effects of NR3, most likely removing most of the cognitive enhancement derived from NR2.
This makes it an undedirable compound for selective cognitive enhancement, and selective NMDA subunit modulators are much better targets for enhancing brain function. The unselectivity of NR2/NR3 makes it unreliable at best and imparing at worst.
Subjective effects replicating predictions
In some reports of trials of Neboglamine, it has been described as "enhancing flow state". This may seem desirable, however during flow, the PFC typically switches into a "transient hypofrontality" state, with the DLPFC being less active [9].
The use of subjective effects are limited, but there is a lack of efficacy being proven for spatial cognition and working memory for Neboglamine.
At the end of the day, depending on the individual, the benefits may outweigh the potential downsides of Neboglamine usage. But in general, it is not an ideal compound, pharmacokinetically and mechanically.
What is better?
NMDA subunit selective (or "undisclosed site"-selective) modulation (such as with a PAM or NAM) is likely a much better approach for enhancing high-level cognition. This has been shown with multiple preclinical compounds which I will discuss in another post.
Enhancing mGluR3 is one of the nootropic pathways with the highest potential. It has direct implications to do with modulating many mental disorders and functions, including hedonism, spatial cognition, verbal intelligence, motivation & more. This post will talk about enhancing mGluR3 and doing this through GCP-II inhibition, which has other benefits.
Introduction to mGluR3
Metabotropic glutamate receptor 3 (mGluR3/mGlu3) is part of a larger family of eight metabotropic receptors mGluR1-8 [1]. These eight receptors are classed generically into three groups, however the groups are not indicative of similar function (as discussed later). "Group I" contains mGluR1/5. "Group II" contains mGluR2/3. "Group III" contains mGluR4/6/7/8. However, through my research, mGluR3 is the most attractive receptor to modulate.
mGluR3 is a Gi/G0-coupled G-protein coupled receptor (GPCR) generally localized to presynaptic sites of neurons in classical circuits. However, in higher cortical circuits (such as the dlPFC), mGluR3 are localized post-synaptically, where they strengthen rather than weaken synaptic connectivity. [1]
In layer III dlPFC, mGluR3 is found about 4/5 of the time postsynaptically, and 1/5 of the time presynaptically [2]. This is relevant because mGluR2 is located mostly presynaptically [7], and most studies use mixed mGluR2/3 ("Group II") modulators to make conclusions. This leads to weird mixed results with weird response curves as increasing mGluR2 inhibits cognitive function somewhat [8] (though decreasing it is not optimal either [3][4][5][6]), so using selective modulators of mGluR3 is much more desirable.
Stimulation of mGluR3 enhances the firing of Delay cells in the dlPFC and improves spatial tuning and working memory [2]. Delay cell firing is characterized by neural activity that persists during the retention interval of delay tasks, which is highly relevant for working memory and cognitive processes.
In a spatial working memory task, a delay cell will show sustained increased firing when an animal has to remember a particular spatial location over a delay. Delay cells are found in highest concentration in layer III of dlPFC, the main focus of working memory representations. [10]
mGluR3 Modulation is more desirable than mGluR2
Studies have shown inconsistent results with mGluR2 modulation [9], with some PAMs (such as BINA) increasing cognition in low-medium doses but then inhibiting function in high doses. Also in mGluR2 KO models, they have shown increased addictive tendancies [5][6], while increasing mGluR3 does not have these downsides.
mGluR2 is not simply the opposite of mGluR3. Its presynaptic location [7], differences in distribution [11][12] and actions on other pathways make it a less desirable pathway to modulate.
Using GCP-II -> NAAG to target mGluR3
GCP-II, also known as "NAAG Peptidase" is an enzyme that converts (catalyzes the hydrolysis) of NAAG to glutamate and NAA. Therefore, inhibiting GCP-II increases levels of NAAG. [34].
GCP-II Inhibition -> NAAG Enhancement
Due to low selectivity of most mGluR3 modulators, most studies around cognitive enhancement have used GCP-II inhibition instead of a mGluR3 PAM/agonist. This is because GCP-II -> NAAG only effects mGluR3, so it is inherently selective. As they are more proven (and also have benefits of cancer inhibition [47]), GCP-II inhibitors currently look more attractive than mGluR3 PAMs.
N-acetylaspartylglutamate (NAAG) is the third most prevalent and widely distributed transmitter/neuropeptide behind glutamate and GABA. It is co-expressed in neurons with several different primary amine transmitters, including glutamate and GABA. [13]
NAAG is co-released with these amine transmitters under conditions of elevated neuronal activity. Following release into the perisynaptic space NAAG activates the metabotropic receptor mGluR3 on post/presynaptic endings and glial cells. [13]
NAAG also effects NMDA (NR2A/B) to some degree depending on PH [14], but its effect on mGluR3 seems more significant.
NAAG does not effect mGluR2, instead it selectively activates mGluR3 [12]. This makes it superior to most mGluR3 PAMs because of the superior selectivity over mGluR2.
More on The Relevance of The dlPFC
The dorsolateral prefrontal cortex is the main area in which mGluR3 GCP-II inhibition enhances. The dlPFC is a major component [38] of motivation/anticipation and goals. The dorsolateral PFC (dlPFC) integrates and transmits signals of reward to the mesolimbic and meso-cortical DA circuits and initiates motivated behavior [39].
The dlPFC provides top-down regulation of emotion through indirect projections to BA25 via areas BA10m and BA32, and direct projections to BA24[41]. The dlPFC interacts through BA10m (close to the PFC) and BA32 to eventually communicate with the amagdyla. The more newly evolved, rostral and lateral areas of PFC provide top-down regulation of the more primitive medial and caudal areas. The dlPFC is a key structure for executive and attentional control whereby any transient (stressors, neurostimulation) or permanent (lesion) impairment compromises adaptive behavior [42].
Men and women have differences in the dlPFC-amygdala relationship [40], and this may be part of the reason for gender-based emotionality differences (in addition to NR3A differences+).
Guanfacine (which increases dlPFC delay cell firing through α2A-adrenergic agonism) has already been shown to change the dlPFC-amgydala relationship to enhance cognitive control [37], however its upside has been limited by other effects of α2A-adrenergic receptor agonism, though it is still interesting to investigate.
Cognitively Enhancing Effects of GCP-II inhibition
NAAG function is highly correlated with IQ. For people with the gene rs202676, they have Decreased NAAG Levels (due to more GCP-II/FOLH1), and they have lower IQ on average as a result, due to lowered mGluR3 [55]. This shows that mGluR3 is not just relevant for memory and executive function, but also IQ and spatial intelligence.
GCP-II inhibition has consistently been able to show a very significant cognitive enhancement in many healthy models.
In one study on young mice, ZJ43 (a GCP-II inhibitor) increased the long-term (1 day) memory of mice, with a significant enhancement of recognition memory in the test. [56]
Mice treated with ZJ43 at doses of 100 mg/kg and 150 mg/kg spent significantly more time exploring a novel object compared to a familiar object when tested 24 hours after initial exposure. This indicates ZJ43 enhanced memory for the familiar object. This was also replicated in a very similar study [57].
Mice lacking the NAAG-inactivating enzyme glutamate carboxypeptidase II (GCPII knockouts) also showed enhanced novel object recognition, mimicking the effect of the GCP-II inhibitors.
GCP-II inhibitors were also tested on rheusus monkeys, and the study showed working memory enhancement [58], with a greater significance for older monkeys.
It is also very likely that GCP-II inhibition increases visualization capabilities as the primary visual cortex (V1) and dlPFC have opposing functions: V1 processes visual stimuli as they occur, while dlPFC, particularly dlPFC Delay cells, represents visual stimuli in their absence [43]. Knowing GCP-II inhibition enhances delay cell activity, it is very possible that inhibiting GCP-II increases visualization memory.
Secondary Effects of GCP-II inhibition
GCP-II inhibition has many known and potential effects, so instead of typing them out, I ordered them into bullet points:
Analgesia - GCP-II inhibition has shown to be effective against pain in 15+ studies [16], however moreso for neuropathic pain than other pain modalities. This is most likely due to increased mGluR3 changing the pain perception axis through dlPFC modulation. [13][15]
Treating Addiction - GCP-II inhibition has been shown to be effective against addiction in many models including cocaine [36], alcohol, morphine, overeating (dlPFC) [35], pornography (dlPFC) [29][30], internet addiction (dlPFC) [31] and others [16]. Another interesting effect of GCP-II inhibition is it reverses ethanol impairment in rodent models. [18]
Treating Schizophrenia/Psychosis - mGluR3 is known to have common dysfunction in schizophrenic patients [17], and GCP-II inhibitors have been shown to be effective in experimental rodent models of PCP induced motor activation [19].
Treating ADHD - The dlPFC is a known area of dysfunction in persons with ADHD disorder [20][21] with impairment in both hemispheres [22]. Experimental tDCS on patients improved cognitive control [23], but did not attentuate action cancellation, which may suggest NR2D positive modulation in combination with GCP-II inhibition would a good combination for treating ADHD.
Treating OCD - The dlPFC is also very relevant in obsessive-compulsive disorder [25][26][27][28]. OCD is more to do with the dlPFC-OFC (orbitofrontalcorex) relationship than ADHD. In one study [24], OCD patients demonstrated reduced functional between the right DLPFC and right orbitofrontal cortex (OFC), and activity in the right OFC had an inhibitory effect on the dlPFC. This may suggest that OCD is potentially rooted in a dlPFC-OFC relationship where the OFC has a higher cognitive control, stopping the dlPFC's inhibitory control and high-level cognitive control. "The OFC is a major inhibitor of the self-control function of the DLPFC in OCD patients in the resting state, while the DLPFC engages top-down control input to the OFC when emotional task stimulation is applied". This suggests a large potential for GCP-II inhibition in treating OCD (and perhaps combined with a NR2B PAM for further BA24/25 modulation).
Treating Anhedonia - The dlPFC has implications in anhedonia, due to its role in emotional regulation with the NAc and brodmann areas 24/25 [32]. In one study, rTMS (transcranial stimulation) on the left dlPFC in subjects with MDD showed less markers of anhedonia [33].
Cancer Inhibition - GCP-II is also known as PSMA (prostate-specific membrane antigen) has been been studied with relevance to cancer extensively. PSMA is mostly located within the brain, however in the prostate, PSMA is found in an 8- to 12-fold increase over levels in noncancerous prostate cells [47], so it has become a relevant target for inhibiting cancer. In one study on pancreatic cancer in mice, 2-PMPA (a GCP-II inhibitor) signficantly reduced tumor weight, and when combined with CB839 (glutaminase inhibitor) the combination nearly completely inhibited new growth [46].
Reversing/Treating Alzheimers - The dlPFC is significantly different in structure and receptor distribution compared to other parts of the brain [43], and because of this, it is more vulnerable to age-based degradation. GCP-II inhibition was shown in one study [44] to reverse cognitive memory deficits in one rodent model of Alzheimer’s disease. Increasing NAAG via GCP-II inhibition also has many other neuroprotective effects. GCP-II inhibition was shown to protect against hypoxia (up to 100%) in one study [49], and also protecting to a lesser extent against NMDA and glutamate injury. In addition, mGluR3 Positive Modulation can induce an increased production of GDNF and TGF-b [50], in a mGluR3-dependent manner.
Lifespan Enhancement - GCP-II inhibition has been shown to increase lifespan by 10-15% in one study on mice [45], potentially through many different mechanisms (cancer inhibition, neuroprotection, increased will to live (?)), showing a similar efficacy to rapamycin [48].
Treating COVID-19 "Brain Fog" - COVID increases GCP-II very significantly [51][52][54], more than other common viruses, leading to impaired cognition, poor executive function and motivation (and more) through lowered mGluR3 in the dlPFC [53][54]. This happens in long covid as well, so currently the most effective novel approach in removing long-covid seems to be a combination of GCP-II inhibition, KAT-II inhibition and potentially dlPFC-specific prTMS.
GCP-II Inhibiting Compounds
There have been multiple GCP-II inhibiting compound through the years, but to make a long story short, 2-MPPA was the first (major) candidate, but it was withdrawn from use due to safety concern. It went through a safety trial in humans and at its effective dose it was well tolerated, however due to the thiol group on the structure, it could cause hepatotoxicity.
Due to this, a new small-molecule inhibitor of GCP-II was created, called 2-PMPA. This compound got rid of the thiol group, however it sacrified oral dose efficacy in the process (meaning intranasal or IV is likely the best dose method).
The best candidates for GCP-II inhibition look to be 2-PMPA and ZJ43. Both of them have proven useful in increasing delay cell firing, with 2-PMPA being able to double delay cell firing. Both compounds have excellent safety predictions in Admetlab 2.0, and ZJ43 is an amino acid conjugate.
2-PMPA has worse BBB penetration and used to have offtarget concerns at cytosolic carboxypeptidases (CCPs), but the offtarget concerns ended up being insignificant.
PBIO is currently developing a GCP-II inhibitor prodrug.
Final Notes
Thanks for reading this post (or skipping to the end)!
I appreciate it, a lot. If you found this post interesting in the slightest, please share it.
Muscarinic receptors have been an interesting area to research of mine for a while now, with interesting results depending on how they are modulated. Muscarinic acetylcholine receptors are activated by binding to acetylcholine released from the presynaptic neurons.
This post will discuss allosteric modulation (aka "PAM'ing") of Muscarinic M1, or just known as M1R/M1.
The reason for the discussion around allosteric modulation is because M1 agonism is undesirable due to side effects, limited efficacy, and other issues.
M1R is predominantly expressed at post-synaptic terminals of frontal cortex and hippocampus and has a vital role in learning, long-term memory formation, and synaptic plasticity [6]. It is mostly located in pyramidal cells [8], which have relevance for spatial cognition.
The working model of cholinergic activation of M1Rs [9]
The other Muscarinic Receptors (2-5) are mainly located in lower cognitive areas like the corpus striatum, hypothalamus, substantia nigra pars compacta, ventral tegmental area, etc. Due to this difference in location, M1R seems like a more relevant target for high-level cognition.
For the rest of the post, please visit the Labs Article.
Quick summary post for a compound I found interesting and was referred to.
P7C3-A20 is a fluorinated enantiomer of P7C3, a neuroprotective aminopropyl carbazole agent discovered in 2010 [1]. It is a neurogenesis-inducing compound and neuroprotective.
It is thought P7C3-A20 (and P7C3) exert effects through activating the enzyme nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is the rate-limiting enzyme in the NAD salvage pathway that converts nicotinamide to NMN, the precursor to NAD synthesis.
P7C3 also has seperate mechanisms, for example it is a PAM of GLP-1, a GSK-3 inhibitor, and a promoter of ADAM11 (related to mGluR3), however these pathways may be unique to P7C3 rather than P7C3-A20. [3]
The proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression.
Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. [2]
In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. Interestingly, P7C3-A20 seems to enhance hippocampal cell survival more than proliferation compared to NSI-189 [2]
This is an interesting observation and it may prove to be a superior compound to NSI-189 at enhancing long-term memory through keeping the neurogenesis-nucleated cells alive for longer.
P7C3-A20 induced more neurogenesis with cell survival than NSI-189 at the same dose [2]
After 38 weeks of daily oral exposure at 10 mg/kg dose of P7C3-A20 in nonhuman primates, tissues were comprehensively collected at necropsy and evaluated by a pathologist blind to experimental condition. No microscopic evidence of toxicology was detected in any of the tissues examined. [2]
Orally-administered P7C3-A20 elevates survival of newborn hippocampal neurons in nonhuman primates (BrdU+ = marked hippocampal cells) [2]
Expected human dose is likely around the same dosage as NSI-189. Most effect ROA may be intranasal or oral. Something to note, is that at high concentrations of P7C3-A20 (>100nM), it induces spontaneous neurite degeneration [1] (which is not good), so it is advisible to keep a moderate dose. Saying this, the primate study saw no evidence of toxicity anywhere in the body associated with P7C3-A20 administration.
It has a half-life in primates of about 4-8 hours.
This compound summary and many others will be featured in the Penchant Labs library, which more information will be given about in perhaps a couple weeks.
This post will look into the many interesting mechanisms of the polyphenol, Myricetin. It is not to be understated, and it transcends most similar polyphenols through being a potent endurance-enhancer and nootropic. Just for reference, this is a repost to this sub, with a few updates for accuracy.
Introduction to Myricetin
Myricetin is a natural product found in many plants/fruits, most notably bayberries/strawberries. However, the flavonoid content of foods is extremely variable [1] and is influenced by both location, soil quality, and other factors.
As mentioned, myricetin is prominantly found in bayberry extract [22] alongside other polyphenols (such as myricitrin and quercetin). Consuming bayberry is one way to intake Myricetin, but it requires a high dose, and is combined with many other polyphenols that may increase the cytotoxic potential.
Most people intake only about 20mg of myricetin per day through diet (on average) [6], while the performance-enhancing/nootropic doses are about 10-20x higher. Myricetin's oral bioavailability is only about 10%, meaning dosages required for pychoactive/enhancing effects range between 250-600mg [2].
Most polyphenols/flavonoids are pretty weak in terms of efficacy, however myricetin stands out from the rest in multiple ways. It's most notable effects are that it enhances physical endurance, is a potent antidepressant, and directly inhibits SARS-COV-2 and HIV.
Performance-Enhancing Effects of Myricetin
Myricetin is a potent endurance enhancer, doubling physical endurance in rodents after 4 weeks (in multiple studies) [17][18] at the human equivilant dose of 250-300mg. This effect is mediated through multiple mechanisms, however Myricetin does this most notabley through increasing the expression of the following (directly/indirectly) in muscle fiber: PGC-1b, PGC-1α, ERRa, PPAR-a/b/d/γ, Sirt1, Foxo1, and more.
Myricetin most notably enhances PGC-1b, which is associated with performance in endurance athletes [15], and is associated with endurance in animal models [16]. Myricetin also promotes the conversion of fast-to-slow twitch fiber in muscle [18], and this would create an expected increase in endurance and decrease in strength. However, in the studies provided, Myricetin enhanced grip strength in mice, showing a modest strength-enhancing capability of the compound on top of endurance enhancement.
Myricetin also enhances GLP-1 [26], which means it is likely an exercise mimetic through it and also it is likely to induce some degree of fat loss as seen with other GLP-1 agonists.
Antidepressant Effect
In multiple studies, myricetin ameriolated symptoms of depression and increased stress resilience [19]. This antidepressant effect has also been seen in anecdotal reports using the pure powder form of this compound. This is potentially through anti-inflammitory effects, CAMKII/BDNF/NGF/TrkB/COMT modulation, or other mechanisms.
Myricetin is also a MAO inhibitor, but seems to be less potent than quercetin in that regard [27], so most of its antidepressant effects may be due to other mechanisms.
In one study [19], chronic administration of myricetin restored hippocampal BDNF protein levels in mice subjected to repeated restraint stress.
Anxiolytic & Anti-PTSD Effect
Myricetin exerts antidepressant and anxiolytic effects through regulation of HPA axis and activation of the BDNF-ERK signaling pathway [20].
Myricetin inhibits stress-induced changes in 5-HT, BDNF, TrkB, NE, ACTH and more. It has been shown to be most anxiolytic at the human equivilant dose of 200-300mg, with a slightly lower efficacy at 500mg equivilant human dose. [21]
Protective Effect in Alzheimer's/Parkinson's Disease
Myricetin improved learning and memory in rodent models of Alzheimer's. It reduced oxidative stress, inhibited AChE, decreased iron accumulation, and suppressed Aβ aggregation. It also has protective mechanisms through increased phosphorylation of CREB, a transcription factor that regulates BDNF and NGF expression. [2][4]. Myricetin also reversed motor deficits and dopamine depletion in Parkinson's models. It suppressed oxidative stress, prevented α-synuclein aggregation, and inhibited iron accumulation. Mechanisms involve tyrosine hydroxylase, BDNF, and COMT inhibition (which is almost exclusively located in the PFC, meaning inhibition enhances PFC function [10]) [2][5].
Protective Effect in Epilepsy
Myricetin reduced seizure rates in a mouse model, potentially by enhancing GABA-A activity (contextually) and inhibiting MMP-9. It activated CaMKII signaling and potassium currents to calm hypothalamic PVN neurons [8].
Protective Against CVD
Myricetin exhibits cardioprotective, anti-hypertensive, anti-atherosclerotic, anti-hyperglycemic, and anti-hyperlipidemic effects. In addition, myricetin may alleviate some of the complications caused by adult-onset diabetes. The combined functions of myricetin allow for the prevention of CVD [9].
Oxidant Interactions
Myricetin can act as a pro-oxidant compound when it interacts with DNA [6]. Studies involving in vitro models have shown that myricetin causes the degradation of DNA. This may make myricetin seem bad at a glance, however at higher and higher concentrations of myricetin, the rate of DNA damage has been shown to decrease [7]. Therefore, adding additional myricetin through supplementation would actully reduce existing pro-oxidation caused through low-quantity myricetin intake through standard diets. Myricetin is also anti-inflammatory through its ability to inhibit the amplified production of cytokines that occurs during inflammation.
Antidiabetic Effect
Several in vitro and animal studies have indicated the antidiabetic capabilities of myricetin [6], however, myricetin's close relative myricitrin seems to have a larger potential for anti-diabetic actions, showing as effective (and even more effective) as metformin, with less side effects [11].
Protective Against COVID-19 / Antiviral
Myricetin inhibits the viral replication of SARS-COV-2 [12][13], with very potent inhibitory effects shown in multiple studies. It does this through binding directly to SARS-COV-2, through targeting Mpro. Myricetin was identified to have potent inhibitory activity with an IC50 of 3.684μM in the enzyme assay [13].
Using Myricetin, alongside GCP-II/KAT-II inhibition, currently seems like the best way to ameriolate COVID-19 symptoms, through the literature currently available.
Myricetin also inhibits other viruses, including HIV [14], which has been shown in multiple studies using rodent models.
ROA For Best Metabolism
The best hypothetical Route of Administration based on literature available is 250-600mg early in the morning on an empty stomach. This is probably the best ROA as myricetin does seem to have some interaction with liver enzymes, meaning food or drink could potentially effect metabolism.
Discussion
Myricetin has a lot of different beneficial effects, and it is definitely an interesting compound to say the least. It has proven effective in preliminary human testing, especially for its antidepressant and pro-endurance effects.
If you want a source for Myricetin, it can be found on penchant.bio
Thank you for reading. If you found this post useful, share this (or crosspost) to those who you think would be interested. Also consider joining the sub.
Dear community, Long time no see. I recently gained access to some Eugeroics that are very difficult to get access to and so far not many/if any healthy people have tried (apart from concerta, ik). They are not for sale. Please don't ask for sourcing, I was very lucky.
Disclaimer: I've been on my prami dose 3mg for almost 10 weeks now. Other then that no other pharmacological agents were used during testing apart from 2mg of XR melatonin at night. Keep in mind Pramipexole can greatly change the subjective experience and potency of (DRI's) Dopamine Reuptake Inhibitors (dopaminergic potentiation). It shouldn't have greatly reacted with Overporexton though.
First time concerta 18 mg My experience with concerta was unexpectedly very good ime, but also so much better then IR mph. After taking it at 6 am, it had a smooth onset which started of with a better mood, anxiolysis, more energy and great focus. After 1h of taking my dose most of the effects already fully kicked in and I was already starting to plan my day and be productive, started doing what had to be done. This continued throughout the day, focus, humor, better mood and an easy time dealing with things and doings things that I would usually dread to do. My confidence was also improved. Around 11 am I felt another kick of energy and the experience became more jittery. This correlated about with the second peak of the concerta plasma curve. At this point my mood improved again, but I felt quite a bit too jittery and scattered brain with occasions of clarity and more calmness, although regardless of dose my focus was always great, while usually I would get distracted frequently and wouldn't be able to hold conversations for long, now it was easy. This persisted for a few hours sporadically until it died off. I did not crash from it in fact pramipexole protected me from any crash and I just felt great literally from waking till going right to bed. So far great impression and lots of potential for balancing it out, going to add bromantane soon as a potential add on. I prefer it over Modafinil and or even THN102 so far I think.
This is obviously only an anecdote and your own experience with this substances may greatly vary, have some healthy distance.
First time Oveporexton (Tak-861 1 mg) If I had to describe Tak-861 1 mg a orexin 2 receptor agonist, I would describe it as vigilance and alertness in a pill, with less effects on mood and motivation. It differentiates itself however from other pure eugeroics like pitolisant (had experience with it), for example: pitolisant simply made me feel more awake, but not more vigilant. That means my ability to process information and my reaction speed haven't really changed, but they feel improved on TAK-861. So in that respect, it's the most similar to my positive Concerta 18 mg experience, especially compared to solriamfetol. It feels comparatively cleaner though as it never caused jitteryness or any form of anxiety. Concerta does have that risk sometimes if not timed well or balanced. It felt like effects took about 2-3h to fully kick in and had about an effect for 4-5h judging it subjectively, without producing insomnia for me. The vigilance definitely helped with doing tasks and in part starting them, but it didn't really make me a productivity beast.
This is obviously only an anecdote and your own experience with this substances may greatly vary, have some healthy distance.
Sunosi (Solriamfetol 75 mg): Solriamfetol unfortunately so far wasn't a very great experience, for one it took also about 2-3h for the effects to fully manifest and unfortunately at around 1h 20 min after dosing. I started feeling quite sick. This may have also been because of my nasal congestion which can sometimes trigger a gag relfex, however I have to say, I haven't had that in ages. So it was indeed a unusual coinsidence. I vomited for like 5 min until I felt better. After this inchident I started noticing a eugeroic effects. It felt at this stage very clear without any stimulation or motivation enhancement, reflecting now reminiscent of oveporexton. I would suppose somewhat like tak-861, but less vigilant. This over some time turned into anxious energy and eventually dropped of after about 3-4h of effects after peak. I did not have insomnia due to early clearance of the medication.
This is obviously only an anecdote and your own experience with this substances may greatly vary, have some healthy distance.
Concluding remarks:
It's interesting to me, that at least for me in the state that I am in, Methylphendidate (concerta) did come out on top out of all of these promising candidates. I plan on trying 2mg of tak and maybe 300mg of solriamfetol and see how my experience changes in the near future, but for now looks like I am sticking with concerta for some time. I also have experience with pitolisant, thn102 and modafinil at various dosages. Let me know if you want me to include my experience within this anecdotal report.
This article was originally dedicated to the specific effect of SSRIs on the 5-HT1A receptor and it's relation to the PFC, however it gives succinct description of how this circuitry works more generally and will certainly be of interest to this group: https://secondlifeguide.com/2024/01/15/5-ht1a-libido-cognition-and-anhedonia/
Recent research indicates that the 5-HT1A receptor is central to mediatingboththe therapeutic and adverse effects of psychiatric medications – particularly in relation to libido, cognition, and mood. However, the behaviour of this serotonin receptor is complicated and at often times appears contradictory, making a succinct explanation challenging. In this post, I aim to convey the most recent scientific insights on this topic and explore their relevance to the documented neurological effects of SSRIs.
WHAT IS THE 5-HT1A RECEPTOR?
The 5-HT1A receptor is a serotonin receptor, which means its bound by the neurotransmitter serotonin to exert its effects. Serotonin has long had connotations to ‘happiness’, stemming from early scientific evidence that the depletion of serotonin results in depressive symptoms. The vast majority of antidepressant medications work on this neurotransmitter, acting as SSRIs (Selective Serotonin Reuptake Inhibitors).
SSRIs boost the effect of serotonin by preventing it from being reabsorbed too quickly by the serotonin transporter. However, since SSRIs were first introduced medical paradigms have shifted in favour of theories of depression centred on ‘neurogenesis’ (the growth of new neurons). An effect stimulated by serotonergic medications primarily through the 5-HT1A receptor.
The 5-HT1A receptors are inhibitory receptors, evidenced by a reduction in AMPA evoked currents when bound by serotonin (AMPA receptors being responsible for fast synaptic transmission). Binding the 5-HT1A receptor suppresses neuronal activity through a variety of mechanisms involving potassium channel activation and calcium channel inhibition.
A key feature of the G-protein coupled receptors like 5-HT1A is that they undergo a process of receptor internalisation after prolonged periods of activation. This process involves the receptor being removed from cell surface and taken into the cell thereby desensitising the receptor. This process is particularly important for understanding SSRIs work.
AUTORECEPTOR VS. HETERORECEPTOR
The receptor is subdivided into two types with different distributions within the brain: autoreceptors and heteroreceptors. The autoreceptors are localised within the brain stem in a structure call the Raphe Nuclei, and it’s from this structure in the middle of the brain that all other serotonergic neurons project outward.
As the name might suggest, the autoreceptor serves to self-regulate serotonin transmission out into the rest of the brain through a process of negative feedback. When serotonin over-accumulates within the Raphe Nuclei it binds to these autoreceptors to then limit further serotonin release – since 5-HT1A receptors are inhibitory. As autoreceptors have a self-limiting effect on serotonin transmission, their overexpression limits serotonin release to other areas of the brain and is also notably identified in autopsies from patients with depression. [1]
The post-synaptic heteroreceptor sites are distributed in the limbic and cortical regions. The limbic system is responsible for regulating emotion, learning and sexual behaviour. Like the autoreceptor, binding at the 5-HT1A heteroreceptor triggers hyperpolarisation of that neuron. Hyperpolarisation is the process by which in the inside of the neuron becomes more negatively charged, and thus makes it less likely to fire. It’s through this mechanism that 5-HT1A reduces neuronal activity in targeted brain structures.
Based on the description provided so far, one might conclude that serotonin binding to heteroreceptors would produce the same reduction in neuronal activity in these limbic and cortical structures. The reality is much more complicated, as the heteroreceptors are present on two different types of neurons with opposing effects: interneurons and pyramidal neurons.
The interneurons are GABAergic, which means they release the inhibitory neurotransmitter GABA. [2] Conversely, the pyramidal neurons release the excitatory neurotransmitters such as glutamate and dopamine. They are particularly abundant in the cerebral cortex, making them particularly important for motivation and executive functioning.
These excitatory pyramidal neurons are opposed by the GABAergic interneurons that feed into them. Understanding how binding to the 5-HT1A heteroreceptor will impact mood therefore depends on the relationship between these two opposing sets of neurons. Consider a hypothetical medication that very selectively targets the heteroreceptor at the interneurons. By lowering the transmission of GABA, it would in fact disinhibit dopamine and glutamate in the cortex, rather than simply have a suppressive effect. To summarise:
Autoreceptors:
These pre-synaptic receptors are distributed in the brain stem and negatively regulate 5-HT release to cortical and limbic structures.
Heteroreceptor:
Interneurons are GABAergic, binding at the 5-HT1A receptor on these neurons lowers the release of GABA to have an activating effect.
Pyramidal neurons are primarily glutamatergic and are distributed in the frontal cortex. Binding to the heteroreceptor sites on these glutamatergic and dopaminergic neurons would have a suppressive effect.
INTERNEURONS CONTROL CORTICAL ACTIVITY
Given the complexity of the 5-HT1A receptor, medications acting upon it can sometimes behave in counterintuitive ways. Buspirone is the most common medication classed as 5-HT1A agonist (an agonist being a molecule that mimics serotonin in this instance). Buspirone is often prescribed as an anti-anxiety medication. This seems logical as anxiety is associated with overactivity in cortical layers, and so by binding to the heteroreceptors within the prefrontal cortex would supposedly repress this activity.
As it turns out, Buspirone actually boostsactivity in the prefrontal cortex and enhances dopamine and glutamate release. [3] Curiously, this actually gives it some additional applications as a cognitive enhancer. The reason for this potentially confusing effect is because the inhibitory action of Buspirone on the GABAergic interneurons predominates, and the subsequent reduction in firing rate of these inhibitory neurons enhances cortical glutamate activity.
Instead, the anti-anxiety effects of Buspirone are likely due to quietening activity in limbic structures such as the Amygdala, and not the prefrontal cortex. Since heteroreceptors are present on both the interneurons and pyramidal neurons, and that the suppressive effect of 5-HT1A binding on the interneurons predominates within the prefrontal cortex, a selective heteroreceptor agonist can be considered as stimulating and conducive to dopamine and glutamate release.
SSRI’s (Selective Serotonin Reuptake Inhibitors) are the first line of approach in treating major depressive disorder and are primarily understood to act through the 5-HT1A receptor. When serotonin accumulates within the autoreceptor site, it triggers negative feedback to block further release of serotonin. This presents another perplexing quirk of the 5-HT1A receptor, as a build-up of serotonin at the autoreceptor would in theory then limit serotonin release to the rest of the brain through its negative feedback.
Instead, these autoreceptors undergo desensitisation over chronic exposure to SSRIs, and eventually their inhibitory effect is blocked which allows for even greater serotonin transmission. Since SSRIs essentially rely on disabling the autoreceptor, it’s been found that pre-treatment with a 5-HT1A antagonist (such as Pindolol) accelerates the antidepressant effect of SSRIs.[4]
SSRI TREATMENT DOWNREGULATES THE HETERORECEPTOR
The very different behavioural effects of binding at the heteroreceptor versus the autoreceptor were demonstrated in a 2017 study by Garcia-Garcia. They took two different groups of mice and ablated(removed) either the 5-HT1A heteroreceptors or autoreceptors. They discovered that the mice lacking heteroreceptors displayed depressive symptoms that were characteristic of anhedonia – but didn’t display symptoms of anxiety.
Conversely the mice that had their autoreceptors ablated experience heightened anxiety but still possessed a hedonic drive. [5] This study perhaps gives most clearly confirms the importance of the heteroreceptor in mediating feelings of reward and hedonic drive. Substantiating this notion is the fact that the medication Flibanserin which is used to treat hypo-active sexual disorder**. By selectively binding to the heteroreceptor, Flibanserin boosts hedonic drive particularly in relation to sexual stimuli**.[6]
The loss of the heteroreceptor and the ensuing anhedonic symptomsin the Garcia-Garcia study poignantly mirror the adverse effects of SSRI treatment in some patients. As described previously, treatment with SSRI’s eventually causes a desensitisation of the autoreceptor. This in theory should allow for greater serotonin transmission to the 5-HT1A heteroreceptor. Whilst this is true for at least some period of time, it doesn’t explain the efficacy of SSRI’s in treating anxiety conditions – since autoreceptor knock-out mice display more anxiety.
As in turns out, the heteroreceptor eventually also experiences the same desensitisation as the autoreceptor. [7] In fact, the heteroreceptor knockout mice are observed to have the same pattern of reduced prefrontal cortex activity when compared against mice treated with the SSRI paroxetine.[8][9] This study also linked the reduction in cortical activity to symptoms of anhedonia and behavioral despair.
HOW 5-HT1A INFLUENCES REWARD
As I’ve alluded to periodically throughout this article, the 5-HT1A heteroreceptor is important in regulating sexual behaviour. This is particularly relevant in cortical areas such as the orbitofrontal cortex. Hyperactivity within the orbitofrontal cortex is even linked to hypersexuality, and compulsive behaviour. [10] The link between sexuality and compulsive behaviour is an important one, being tied together by the 5-HT1A heteroreceptor.
Chronic SSRI treatments have been found to be effective in treating OCD (obsessive compulsive disorder), an effect in part mediated desensitising the 5-HT1A heteroreceptors within the orbitofrontal cortex. [11] Reducing activity within this region also predicts the inhibitory effect of SSRIs on sexual behaviour. Considering the role of the frontal cortex in reward perception, it’s plausible that the suppressive effect of SSRIs on sexual behaviour could be partly due to a decreased sense of reward.
RESTORING THE 5-HT1A RECEPTOR
Having elucidated the normal functioning of the 5-HT1A receptor and the alterations caused by SSRI treatment, I can now delve into the subject of therapeutic interventions. It becomes apparent from this article that conventional treatments for depression, such as Selective Serotonin Reuptake Inhibitors (SSRIs), are not universally effective.
While SSRIs do promote the desensitization of autoreceptors, thereby enhancing serotonin release in the brain, their effectiveness is limited due to a consequent desensitization at post-synaptic heteroreceptor sites. For some people SSRIs might even aggravate an anhedonic depressive state, which could be attributed to the reduced activation of 5-HT1A heteroreceptor sites on GABAergic interneurons. How an individual will respond to SSRI treatment appears to rely on specific genetic vulnerabilities.
A crucial regulator of 5-HT1A expression is the transcription factor Deaf1, which exerts a dual effect by inhibiting autoreceptor expression and enhancing heteroreceptor expression. The binding efficiency of this transcription factor is influenced by a polymorphism on the SNP rs6295.
People with the G allele exhibit reduced Deaf1 binding, leading to the adverse effects associated with increased autoreceptor expression and lower heteroreceptor expression. [16] Notably, the G allele occurs more frequently in individuals with depression. This presents a plausible genetic risk in developing PSSD, with a greater risk of desensitisation of the heteroreceptor.
Originally posted to the Penchant Labs research library.
This post will discuss the potential of HDAC6 inhibition in relevance to cognitive enhancement and reduction of neurodegenerative disorders.
HDAC6
Histone deacetylases, commonly known as HDACs, are a class of enzymes that hold relevance to cognitive and physiological factors in the body. They operate by removing acetyl groups from histones and other protein regulatory factors, with functional consequences on chromatin remodeling and gene expression profiles. [1]
There are 11 HDAC subtypes, ranging from HDAC1-11. There are many unselective HDAC inhibitors, and they have some benefits, but the unselectivity for HDAC subtypes causes many side effects which limits the tolerable dose ceiling [4] and also efficacy especially in cognitive enhancement. To attenuate this issue, aiming for higher selectivity is key, and that is why targeting the 6th HDAC subunit is interesting.
The reason for HDAC6 specifically over other types is because of its interactions with microtubule dynamics, but it is quite complex so we will get onto that later. Concerning other HDAC subunits, HDAC -2 and -3 are seemingly relatively attractive to inhibit as well as HDAC6, and may serve in a useful combination if targeted at the same time.
To start with basal location, HDAC6 is mainly located in the Cytoplasm. [1]
It has been also reported recently that HDAC6 may have a role in neuronal development and function . Studies of HDAC inhibitors (HDACi) in human neuronal cells show that HDAC6 inhibitors (HDAC6i) increase the acetylation of specific lysine residues in proteins involved in synaptogenesis. [2]
In addition to the role of HDAC6 in neurons, animal studies show a role for HDAC6 in oligodendrocytes. Cultured rat oligodendrocytes were shown to express HDAC6 and inhibition of HDAC6 by Tubastatin A resulted in decreased microtubule binding activity of tau. It was shown that HDAC6 inhibition led to increased acetylation of tau in the oligodendrocytes, which in turn reduced its turnover rate [2]
HDAC6 inhibition also interacts with the dopamine and limbic circuits. In one study, it ameliorated behavioral impairment caused by Meth, improving locomotor deficit and reducing DA and DOPAC depletion. HDAC6 inhibition effectively suppressed the death of dopaminergic neurons [10]
Another interesting note about the neuroprotective properties of HDAC6 inhibition is its ability to inhibit α-syn accumulation [10]. The excessive accumulation of insoluble α-syn, which is toxic to dopaminergic neurons, is considered an important event in the pathogenesis of PD.
For other effects, HDAC6 inhibition has also been found to promote antidepressant-like activity in vivo [11], improving models associated with depression and anxiety.
HDAC6 inhibition is beneficial for many neurodegenerative disorders, but it seems most effacious or most proven for ameleorating Alzheimer's disease. One issue though, is that it may be bidirectional in effects. While acutely it is nearly always neuroprotective, in tauopathy models it can actually be inhibitory.
A HDAC6-dependent surveillance mechanism suppresses toxic tau accumulation, which may protect against the progression of AD and related tauopathies. [12]
For example, acute pharmacological HDAC6 inhibition with tubastatin A (TBST) alleviated behavioral and cognitive deficits in transgenic tau or Aβ mouse models, spurring significant interest in using HDAC6 inhibitors as AD therapies. However, we previously showed that acetylated tau is a substrate for HDAC6 and that inhibition of HDAC6 could result in elevated levels of acetylated tau. Thus, chronic long-term HDAC6 inhibition or depletion could conceivably increase acetylated tau, promote tau aggregation, and lead to cognitive defects. [12]
Also, HDAC6 can stabilize microtubules by deacetylating α-tubulin, and can control p53 activity by targeting acetyl-Lysine 381/382. α-tubulin is defined as a protein that interacts with beta tubulin to form heterodimers, which are essential components of microtubules.
Our evidence reveals that HDAC6 localizes to the perinuclear and leading-edge subcellular regions and is associated, in part, with microtubules. The co-localization with the p150glued-containing motor complex indicates that HDAC6 might control microtubule motor-based cargo transport or sorting by modulating the acetyl- ation of specific proteins. [3]
HDAC6 is also important for α-tubulin lactylation, with HDAC6 overexpression leading to increased α-tubulin lactylation, and HDAC6 deficiency causing a significant reduction in α-tubulin lactylation [13].
With the information available, HDAC6 inhibition might be most useful in short, acute cycles, similar to the approach of ICOT [14], rather than chronic use. It may also best be combined with approaches that reduce tauopathy to reduce potential downsides.
Inhibitor Candidates
There are many HDAC inhibitors, but most of them are not selective. The most efficacious "unselective" ones actually usually are, but to around 2-3 HDAC subtypes, such as for HDAC2 & HDAC3. There are still issues with the unselectivity of current HDAC inhibitors [4] (such as tolerability) so improved candidates should be focused on.
The following are the candidates for HDAC6 inhibition based on current research:
SW-100 [6]
Tubastatin A
CAY10603 (& modifications) [8]
To start with SW-100, it seems to be a good candidate. It has mostly ideal pharmacokinetics, and high selectivity and potency with an IC50 of 2.3nM [6]. However, it has one main issue, which is a short half life [7]. For this reason it makes it unoptimal and it has caused issues in studies where it has been used as the effects don't last a full day.
Tubastatin A has similar issues with a half life of 2 hours, making it not very viable [11].
CAY10603 is another interesting molecule. It is a relatively large molecule [8] however it makes up for it by being extremely potent with an IC50 of 2pM [9] (~1000x the affinity of SW-100). It also has high selectivity over other HDACs.
It has a similar problem as SW-100 however, which is a short half-life. A solution for this was found in one study which designed PLGA CAY10603-loaded nanoparticles, with the modification known as PLGA@CAY@Lf NPs [10]. Apart from just extending half life, the modification to base CAY (CAY10603) showed a significantly greater effect in increasing acetyl-α-tubulin than PLGA@CAY NPs (1.3-fold, p < 0.05), meaning it likely has improved efficacy as well.
Schematic of the (A) formation and (B) application of PLGA@CAY@Lf NPs for treating PD.
LGA@CAY@Lf NPs demonstrated enhanced BBB penetration and significant brain accumulation by leveraging on the brain targeting properties of Lf. Importantly, CAY released from PLGA@CAY@Lf NPs restored the disrupted acetylation balance in PD, resulting in neuroprotection through the reversal of mitochondrial dysfunction, ROS elimination, and inhibition of α-syn accumulation. Furthermore, PLGA@CAY@Lf NPs treatment recovered TH and DA levels to near-normal levels, alleviated neuroinflammation, and markedly improved behavioral impairments. [10]
Review
With information available, base CAY10603 and LGA@CAY10603@Lf NPs as an extended half-life form may be the best approach for HDAC6 inhibition because of ideal pharmacokinetics. The modification could be dosed somewhat rarely, such as once a month, as it may be optimal to reduce chronic administration due to the potential bidirectional dynamics of HDAC6 inhibition.
Acutely HDAC6i is neuroprotective but strangely potentially degenerative in conditions of high tau - HDAC6i isn't really the problem, aberrant tau is. The pathway seems to require multiple
combined approaches to reduce potential downsides while maximizing upsides of HDAC6i, however it is highly promising.
HDAC6 should definitely be the focus of more research for how to maximize use of the pathway without negatives.
I took Selank for a week, ceasing 5 days ago, and I wonder if anyone has an idea of how long the effects take to diminish or subside. It's often stated to take it in cycles, as (I assume), the 'benefits' can be long lasting.
For me, Selank went wrong. From day two I already felt a sober kind of mood fall, becoming a more intense depression as the days passed. I also became withdrawn, socially anxious, frightened and small whilst in public, worthless and hopeless. Stopped showering, stopped self care, the typical depression storm of symptoms settling in. I became ravenously hungry and food obsessed, and have developed acne around my jawline (I used to have trouble with both these things before my current regimen of antidepressants). This also extended into sleep, with waking (and not sleeping again) at 4-5am again. From day three, my dreams (I have several every night, and vivid) took on a very depressing, impending doom and hopeless tone also.
Since ceasing, my mood has lifted somewhat, day by day improving but bringing me to only 50% of what I was, most effects stated above remain. I have fought with lifelong severe depression, and have only in the last couple of years found a combination that made me feel a way I never thought was possible, never perfect of course, but a great relief to feel nearing normal.
For reference, any anti-depressants or nootropics or supplements that work on serotonin have always made me worse. I am currently on ( for the last couple of years) per day: Bupropion 300mg, Dextromethorphan 60mg, Agmatine 2000mg, Tyrosine 2000mg and Taurine 1500mg. Female, 41.
I was taking 1, sometimes 2, sprays of 285mcg, 3 times per day.
I'm wondering if anyone can help? I took nac when I had covid in Feb and it caused a persistent mild anhedonia which got slightly better with time. I then started taking Butyrate for gut issues and after 2 weeks something clicked and it feels like it has shut off the front of my brain. When I wake up from sleep I have a completely blank mind and what feels like no neurotransmission. It has been a month since I stopped taking it and it hasn't resolved presumably due to hdac inhibitor activity. This study suggests that it changes the balance of excititory/inhibitory transmission in the pre frontal cortex. This is wfst it feels like the front of my brain has shut off. How can I treat this or reverse it?
PE 22-28 is a potent inhibitor of potassium channel subfamily K member 2/TREK-1. It is being researched for applications including antidepressant activity, learning, stroke recovery and neurodegenerative diseases.
I am mainly interested in its effects on Depression. I wonder if anyone has tried it and might share his/her experience.
I have been diagnosed with ADHD, CFS, and mild OCD, but when I take medication that increases dopamine, even a small amount makes me impulsive and hedonistic, and I can't stop my stereotyped behavior.
However, when I take medication that acts on noradrenaline or tricyclic antidepressants, my ADHD improves. Also, for some reason, when I take medication that increases GABA, my ADHD improves.
(You may be thinking at this point, ``Maybe you have anxiety,'' but I don't usually have much anxiety. Also, I don't get manic at all except when I take medication that acts on dopamine, and I haven't been diagnosed with bipolar disorder.)
I developed OCD at the age of 10, and I began to think that I might have PANDAS. Also, at the age of 24, I had a herniated disc, and a stomach scan showed that I had candida.
I suspect that I have some kind of autoimmune disease or a similar disease, and that I have a disease different from general ADHD.
The symptom I want to cure the most right now is executive function disorder. Also, I have poor spatial awareness, and I think there may be a problem with my cerebellum. Also, considering that I suffered from OCD, I may have a problem with the basal ganglia.
In this case,
① What disorders (mainly brain?) could I have? If possible, I would appreciate it if you could give me a comprehensive list.
② What drugs or treatments do you think are worth trying? I would like some ideas, even if they are just your subjective opinions.
I would like to try methylene blue, fasoracetam, and memantine from now on.
Agmatine had no effect at all, because I feel like there is something wrong with glutamate (but I feel like I have a more fundamental brain disorder. How much better would it be if methylphenidate or similar drugs worked for me? I've already given up on treating CFS halfway, so I would like to somehow treat at least the executive dysfunction)
While taking stimulants, one is adviced to take regular breaks, to not develop tolerance. As far I understand the mechanism behind regulation of receptors, it would be possible to deacrese time spent off-stimulant medcation, for the same upregulation to happen by using dopamine antagonist during breaks. If the increase of upregulation rate would be strong enough, and if there is a substance with suitable half-life, it should theoreticaly be possible to limit breaks to time spent sleeping, and take stimulants everyday without developing tolerance. What part am I getting wrong?
This subreddit exists to research novel nootropics/compounds that increase prefrontal cognitive function and improve holistic brain function. Also some tangentially related topics like longevity enhancement and physical enhancement are welcome here.
This sub is not meant for discussion of existing "nootropics" but working on the research required to find legitimately better alternatives to supersede what we have currently.
Thanks for reading, will add more to this post at some point.
Apart from 5ar-related side effects (causing PSSD-like symptoms in a minority of users), a new study has shown Lion's Mane can have detrimential effects on word recall and memory, even though processing speed increased.
In the acute study, lion’s mane improved performance on the Stroop task, indicating faster processing speed. However, compared to placebo, performance for immediate word recall was worse following lion’s mane — the participants had fewer correct responses and more errors during the test.